Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Target Therapy Guided by ctDNA-MRD in EGFR-mutant NSCLC
NCT06323148Phase 3Not yet recruiting
- Sponsor
- Fudan University
- Start
- Apr 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Fudan University. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06323148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06323148.